All Tezspire (tezepelumab) articles
-
NewsNew Phase III Tezspire data signals advance in epithelial-driven inflammatory disease treatment
First-in-class monoclonal antibody significantly improved both underlying inflammation and dysphagia in eosinophilic esophagitis, extending its potential beyond the airways to the oesophagus.
-
NewsAstraZeneca’s tezepelumab and dapagliflozin accepted for use in Scotland
The Scottish Medicines Consortium (SMC)’s acceptance means eligible patients across the UK can now benefit from AstraZeneca's Tezspire (tezepelumab) for severe asthma and Forxiga (dapagliflozin) for chronic heart failure.
-
NewsPre-filled asthma pen approved for self-administration in EU
Tezspire is the first biologic approved in Europe for severe asthma with no phenotype or biomarker limitation, says AstraZeneca EVP.